Despite the recent approval of targeted biologics that can significantly improve quality of life, Canadians living with Myasthenia Gravis continue to face unjust policy barriers.
We are told health care in Canada is equal for everyone. But it is not. Particularly for patients with neuromuscular diseases, what you get depends on where you live.